促甲状腺激素受体激动剂和拮抗剂的最新进展。
Update in TSH receptor agonists and antagonists.
机构信息
Laboratory of Endocrinology and Receptor Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
出版信息
J Clin Endocrinol Metab. 2012 Dec;97(12):4287-92. doi: 10.1210/jc.2012-3080. Epub 2012 Sep 27.
Abstract
The physiological role of the TSH receptor (TSHR) as a major regulator of thyroid function is well understood, but TSHRs are also expressed in multiple normal extrathyroidal tissues, and the physiological roles of TSHRs in these tissues are unclear. Moreover, TSHRs play a major role in several pathological conditions including hyperthyroidism, hypothyroidism, and thyroid tumors. Small molecule, "drug-like" TSHR agonists, neutral antagonists, and inverse agonists may be useful as probes of TSHR function in extrathyroidal tissues and as leads to develop drugs for several diseases of the thyroid. In this Update, we review the most recent findings regarding the development and use of these small molecule TSHR ligands.
摘要
促甲状腺激素受体（TSHR）作为甲状腺功能主要调节剂的生理作用已被充分理解，但 TSHR 也在多种正常甲状腺外组织中表达，其在这些组织中的生理作用尚不清楚。此外，TSHR 在包括甲状腺功能亢进、甲状腺功能减退和甲状腺肿瘤在内的多种病理情况下发挥重要作用。小分子“类药” TSHR 激动剂、中性拮抗剂和反向激动剂可作为研究 TSHR 在甲状腺外组织中功能的探针，并可作为开发几种甲状腺疾病药物的先导化合物。在本综述中，我们回顾了关于这些小分子 TSHR 配体的最新发现及其开发和应用。
相似文献
1
Update in TSH receptor agonists and antagonists.促甲状腺激素受体激动剂和拮抗剂的最新进展。
J Clin Endocrinol Metab. 2012 Dec;97(12):4287-92. doi: 10.1210/jc.2012-3080. Epub 2012 Sep 27.
2
Small molecule TSHR agonists and antagonists.小分子 TSHR 激动剂和拮抗剂。
Ann Endocrinol (Paris). 2011 Apr;72(2):74-6. doi: 10.1016/j.ando.2011.03.002. Epub 2011 Apr 20.
3
A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism.一种对人促甲状腺激素受体具有低分子量拮抗作用且对甲状腺功能亢进症有治疗潜力的物质。
Endocrinology. 2008 Dec;149(12):5945-50. doi: 10.1210/en.2008-0836. Epub 2008 Jul 31.
4
TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities.具有激动剂、拮抗剂和反向激动剂活性的促甲状腺激素受体单克隆抗体。
Methods Enzymol. 2010;485:393-420. doi: 10.1016/B978-0-12-381296-4.00022-1.
5
New small molecule agonists to the thyrotropin receptor.促甲状腺激素受体的新型小分子激动剂。
Thyroid. 2015 Jan;25(1):51-62. doi: 10.1089/thy.2014.0119.
6
Central dogma in thyroid dysfunction: a review on structure modification of TSHR as a cornerstone for thyroid abnormalities.甲状腺功能障碍的中心法则：关于促甲状腺激素受体结构修饰作为甲状腺异常基石的综述
Pak J Biol Sci. 2011 Feb 1;14(3):170-81. doi: 10.3923/pjbs.2011.170.181.
7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.一种人类促甲状腺激素受体的小分子反向激动剂。
Endocrinology. 2010 Jul;151(7):3454-9. doi: 10.1210/en.2010-0199. Epub 2010 Apr 28.
8
Small-molecule thyrotropin receptor agonist activates naturally occurring thyrotropin-insensitive mutants and reveals their distinct cyclic adenosine monophosphate signal persistence.小分子促甲状腺激素受体激动剂激活天然存在的促甲状腺激素不敏感突变体，并揭示其独特的环腺苷酸信号持续时间。
Thyroid. 2011 Aug;21(8):907-12. doi: 10.1089/thy.2011.0025. Epub 2011 Jul 11.
9
Discovery of a Positive Allosteric Modulator of the Thyrotropin Receptor: Potentiation of Thyrotropin-Mediated Preosteoblast Differentiation In Vitro.促甲状腺激素受体正变构调节剂的发现：体外增强促甲状腺激素介导的前成骨细胞分化
J Pharmacol Exp Ther. 2018 Jan;364(1):38-45. doi: 10.1124/jpet.117.244095. Epub 2017 Oct 31.
10
Thyrotropin receptor antagonists and inverse agonists, and their potential application to thyroid diseases.促甲状腺激素受体拮抗剂和反向激动剂及其在甲状腺疾病中的潜在应用。
Endocr J. 2022 Nov 28;69(11):1285-1293. doi: 10.1507/endocrj.EJ22-0391. Epub 2022 Sep 27.
引用本文的文献
1
Tailoring TSH suppression in differentiated thyroid carcinoma: evidence, controversies, and future directions.分化型甲状腺癌中促甲状腺激素抑制的个体化：证据、争议及未来方向
Endocrine. 2025 Apr 9. doi: 10.1007/s12020-025-04223-w.
2
Low-molecular-weight Ligand of the Thyroid-stimulating Hormone Receptor with the Activity of a Partial Agonist and a Negative Allosteric Modulator.具有部分激动剂和负变构调节剂活性的促甲状腺激素受体低分子量配体
Dokl Biochem Biophys. 2025 Feb;520(1):53-57. doi: 10.1134/S1607672924600799. Epub 2025 Jan 22.
3
Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer.用于甲状腺癌中促甲状腺激素受体表达PET成像的锆-89标记抗体K1-70
Mol Imaging Biol. 2024 Oct;26(5):847-857. doi: 10.1007/s11307-024-01945-7. Epub 2024 Aug 22.
4
Cryo-electron microscopy for GPCR research and drug discovery in endocrinology and metabolism.冷冻电镜在内分泌和代谢领域的 GPCR 研究和药物发现中的应用。
Nat Rev Endocrinol. 2024 Jun;20(6):349-365. doi: 10.1038/s41574-024-00957-1. Epub 2024 Feb 29.
5
An Orally Efficacious Thyrotropin Receptor Ligand Inhibits Growth and Metastatic Activity of Thyroid Cancers.一种口服有效的促甲状腺激素受体配体可抑制甲状腺癌的生长和转移活性。
J Clin Endocrinol Metab. 2024 Aug 13;109(9):2306-2316. doi: 10.1210/clinem/dgae114.
6
Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer.促甲状腺激素在甲状腺癌患者临床疗效中的价值及安全性分析
World J Clin Cases. 2023 Feb 16;11(5):1058-1067. doi: 10.12998/wjcc.v11.i5.1058.
7
Prospects of Testing Diurnal Profiles of Expressions of TSH-R and Circadian Clock Genes in Thyrocytes for Identification of Preoperative Biomarkers for Thyroid Carcinoma.检测甲状腺细胞中 TSH-R 和昼夜节律基因表达的日间谱以鉴定甲状腺癌术前生物标志物的前景。
Int J Mol Sci. 2022 Oct 13;23(20):12208. doi: 10.3390/ijms232012208.
8
The Mysterious Universe of the TSH Receptor.促甲状腺激素受体的神秘宇宙。
Front Endocrinol (Lausanne). 2022 Jul 12;13:944715. doi: 10.3389/fendo.2022.944715. eCollection 2022.
9
Modulating TSH Receptor Signaling for Therapeutic Benefit.调节促甲状腺激素受体信号以获得治疗益处。
Eur Thyroid J. 2020 Dec;9(Suppl 1):66-77. doi: 10.1159/000511871. Epub 2020 Nov 23.
10
Graves' disease.格雷夫斯病。
Nat Rev Dis Primers. 2020 Jul 2;6(1):52. doi: 10.1038/s41572-020-0184-y.
本文引用的文献
1
A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts.一种类药物拮抗剂抑制 Graves 眼眶成纤维细胞中促甲状腺激素受体介导的 cAMP 产生的刺激作用。
Thyroid. 2012 Aug;22(8):839-43. doi: 10.1089/thy.2011.0520. Epub 2012 Jul 11.
2
Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter.重组人促甲状腺激素（rhTSH）预处理可改善多结节性非毒性甲状腺肿放射性碘治疗的长期疗效。
J Clin Endocrinol Metab. 2012 Aug;97(8):2653-60. doi: 10.1210/jc.2011-3335. Epub 2012 May 10.
3
Hypothyroidism: etiology, diagnosis, and management.甲状腺功能减退症：病因、诊断与治疗。
Med Clin North Am. 2012 Mar;96(2):203-21. doi: 10.1016/j.mcna.2012.01.005. Epub 2012 Feb 14.
4
Complete inhibition of rhTSH-, Graves' disease IgG-, and M22-induced cAMP production in differentiated orbital fibroblasts by a low-molecular-weight TSHR antagonist.一种低分子量 TSHR 拮抗剂完全抑制分化的眼眶成纤维细胞中 rhTSH、Graves 病 IgG 和 M22 诱导的 cAMP 产生。
J Clin Endocrinol Metab. 2012 May;97(5):E781-5. doi: 10.1210/jc.2011-2931. Epub 2012 Mar 14.
5
Skeletal receptors for steroid-family regulating glycoprotein hormones: A multilevel, integrated physiological control system.甾体家族调节糖蛋白激素的骨骼受体：一个多层次、综合的生理控制系统。
Ann N Y Acad Sci. 2011 Dec;1240:26-31. doi: 10.1111/j.1749-6632.2011.06287.x.
6
Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor.一种纳米级强效、变构甲状腺刺激激素受体拮抗剂的作用机制。
Br J Pharmacol. 2012 Apr;165(7):2314-24. doi: 10.1111/j.1476-5381.2011.01709.x.
7
Small-molecule thyrotropin receptor agonist activates naturally occurring thyrotropin-insensitive mutants and reveals their distinct cyclic adenosine monophosphate signal persistence.小分子促甲状腺激素受体激动剂激活天然存在的促甲状腺激素不敏感突变体，并揭示其独特的环腺苷酸信号持续时间。
Thyroid. 2011 Aug;21(8):907-12. doi: 10.1089/thy.2011.0025. Epub 2011 Jul 11.
8
Thyrotropin receptor stimulates internalization-independent persistent phosphoinositide signaling.促甲状腺素受体刺激非内吞作用依赖性持续的磷酯酰肌醇信号转导。
Mol Pharmacol. 2011 Aug;80(2):240-6. doi: 10.1124/mol.111.072157. Epub 2011 Apr 27.
9
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.促甲状腺激素受体信号对小鼠 BRAF 诱导甲状腺肿瘤起始的依赖性。
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1615-20. doi: 10.1073/pnas.1015557108. Epub 2011 Jan 10.
10
A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor.一种新的小分子拮抗剂抑制 Graves 病抗体激活 TSH 受体。
J Clin Endocrinol Metab. 2011 Feb;96(2):548-54. doi: 10.1210/jc.2010-1935. Epub 2010 Dec 1.
Zotero 插件